| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Citigroup analyst Yigal Nochomovitz maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and lowers the price target f...
TD Cowen analyst Phil Nadeau maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and lowers the price target from $50...
Baird analyst Colleen Kusy maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Outperform and raises the price target fro...
HC Wainwright & Co. analyst Douglas Tsao maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and lowers the price...
Apellis Pharmaceuticals (NASDAQ:APLS) reported quarterly earnings of $1.67 per share which beat the analyst consensus estimate ...
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced new data from the open-label period of the Phase 3 VALIANT study th...